2001 (Cycle VII)
Innovative Awards: IDEA (Innovative, Developmental, and Exploratory Awards) Top
| Novel Enzymes Associated with Breast Cancer Angiogensis | ||||
| University of California, San Francisco | ||||
| Research Priority: Pathogenesis > Outbreak - how cancer spreads | ||||
| Award Type: IDEA | ||||
| Are EGF-Receptors Activated by IL-8 in Breast Cancer? | ||||
| La Jolla Institute for Molecular Medicine | ||||
| Research Priority: Pathogenesis > Unraveling the path to breast cancer | ||||
| Award Type: IDEA | ||||
| Targeting of Tumor-Promoting Galectins in Breast Cancer | ||||
| Sidney Kimmel Cancer Center | ||||
| Research Priority: Imaging, Biomarkers, & Molecular Pathology > Biomarkers & novel screening | ||||
| Award Type: IDEA | ||||
| Evaluation of Essiac Tea to Prevent Mammary Tumors | ||||
| Lawrence Livermore National Laboratory | ||||
| Research Priority: Prevention & Risk Reduction > Other searches for the causes | ||||
| Award Type: IDEA | ||||
| Novel Technologies to Identify Tissue-Selective Estrogens | ||||
| University of California, San Francisco | ||||
| Research Priority: Innovative Treatments > Hormone and chemotherapy targets | ||||
| Award Type: IDEA | ||||
| Rodent Model for Human Ductal Carcinoma in Situ | ||||
| University of California, Berkeley | ||||
| Research Priority: Pathogenesis > Unraveling the path to breast cancer | ||||
| Award Type: IDEA | ||||
| Smoking Effect on Pulmonary Metastasis from Breast Cancer | ||||
| University of California, Davis | ||||
| Research Priority: Pathogenesis > Outbreak - how cancer spreads | ||||
| Award Type: IDEA | ||||
Collaboration Awards: CRC (Community Research Collaboration) Full Research Awards Top
| Return to Work after Breast Cancer Surgery | ||||
| Women's Cancer Resource Center | ||||
| Research Priority: Health Policy & Health Services > Health Policy & Health Services | ||||
| Award Type: CRC Full | ||||
| Does a Peer Navigator Improve Quality of Life at Diagnosis? | ||||
| Stanford University | ||||
| Research Priority: Health Policy & Health Services > Health Policy & Health Services | ||||
| Award Type: CRC Full | ||||
Collaboration Awards: SPRC (Scientific Perspectives Research Collaboration) Exploratory Awards Top
Collaboration Awards: TRC (Translational Research Collaboration) Pilot Awards Top
| Dietary Indole Effect on Estrogen Urinary Metabolites | ||||
| University of California, Berkeley | ||||
| Research Priority: Innovative Treatments > Hormone and chemotherapy targets | ||||
| Award Type: TRC Pilot | ||||
Career Development Awards: Postdoctoral Fellowship Top
| Engineering Antibodies Specific for Breast Cancer Proteases | ||||
| University of California, San Francisco | ||||
| Research Priority: Innovative Treatments > Immune therapy | ||||
| Award Type: Postdoctoral Fellowship | ||||
| The Role of SGK in Breast Cancer Proliferation | ||||
| Scripps Research Institute | ||||
| Research Priority: Pathogenesis > Cell growth | ||||
| Award Type: Postdoctoral Fellowship | ||||
| Genetic Analysis of ErbB Signaling in C. Elegans | ||||
| California Institute of Technology | ||||
| Research Priority: Pathogenesis > Cell growth | ||||
| Award Type: Postdoctoral Fellowship | ||||
| Molecular Study of BAG Domains: A New Motif in Breast Cancer | ||||
| The Burnham Institute for Medical Research | ||||
| Research Priority: Pathogenesis > Cell growth | ||||
| Award Type: Postdoctoral Fellowship | ||||
| The Role of BRCA1 in Nucleotide Excision Repair | ||||
| Stanford University | ||||
| Research Priority: Pathogenesis > Mistakes on the master blueprint | ||||
| Award Type: Postdoctoral Fellowship | ||||
| Molecular Characterization of ErbB2 Positive Breast Cancers | ||||
| Buck Institute for Age Research | ||||
| Research Priority: Pathogenesis > Cell growth | ||||
| Award Type: Postdoctoral Fellowship | ||||
| SBP-1: A Novel Survivin Binding Protein in Breast Cancer | ||||
| The Burnham Institute for Medical Research | ||||
| Research Priority: Pathogenesis > Cell growth | ||||
| Award Type: Postdoctoral Fellowship | ||||
| Regulation of the ATR Checkpoint Response in Breast Cancer | ||||
| Stanford University | ||||
| Research Priority: Pathogenesis > Mistakes on the master blueprint | ||||
| Award Type: Postdoctoral Fellowship | ||||
| Genes That Modulate Dioxin-Induced Breast Cancer | ||||
| Stanford University | ||||
| Research Priority: Pathogenesis > Unraveling the path to breast cancer | ||||
| Award Type: Postdoctoral Fellowship | ||||
| Protein Factor PPARg & Vitamin A Compounds in Breast Cancer | ||||
| The Burnham Institute for Medical Research | ||||
| Research Priority: Innovative Treatments > New drug design | ||||
| Award Type: Postdoctoral Fellowship | ||||
| Lasp-1 Signaling in Breast Carcinoma Cell Invasion/Migration | ||||
| Scripps Research Institute | ||||
| Research Priority: Pathogenesis > Outbreak - how cancer spreads | ||||
| Award Type: Postdoctoral Fellowship | ||||
| P132Cas and Antiestrogen Resistance of Breast Cancer | ||||
| The Burnham Institute for Medical Research | ||||
| Research Priority: Pathogenesis > Cell growth | ||||
| Award Type: Postdoctoral Fellowship | ||||
| Analysis of a Protease Involved in Mammary Development | ||||
| Lawrence Berkeley National Laboratory | ||||
| Research Priority: Biology of the Normal Breast > Breast development | ||||
| Award Type: Postdoctoral Fellowship | ||||
| Telomere Clustering is Lost in Mammary Epithelial Tumors | ||||
| Lawrence Berkeley National Laboratory | ||||
| Research Priority: Biology of the Normal Breast > Breast aging | ||||
| Award Type: Postdoctoral Fellowship | ||||
Collaboration Awards: TRC (Translational Research Collaboration) Full Research Awards Top
Innovative Awards: STEP Award Top
| Role of Id-2 in Breast Cancer and its Relationship to Id-1 | ||||
| California Pacific Medical Center Research Institute | ||||
| Research Priority: Pathogenesis > Unraveling the path to breast cancer | ||||
| Award Type: STEP | ||||
| Selective Targeting of Breast Cancer with Radioiodide | ||||
| Stanford University | ||||
| Research Priority: Innovative Treatments > Gene therapy & other treatments | ||||
| Award Type: STEP | ||||
| A New Genetic Vaccine Therapy for Breast Cancer | ||||
| University of California, Irvine | ||||
| Research Priority: Innovative Treatments > Immune therapy | ||||
| Award Type: STEP | ||||
| Blood Vessel Markers in Breast Cancer | ||||
| The Burnham Institute for Medical Research | ||||
| Research Priority: Innovative Treatments > New drug design | ||||
| Award Type: STEP | ||||
| Overcoming Drug Resistance in Breast Cancer | ||||
| The Burnham Institute for Medical Research | ||||
| Research Priority: Pathogenesis > Unraveling the path to breast cancer | ||||
| Award Type: STEP | ||||
| Early Detection of Breast Cancer and it Recurrence | ||||
| Huntington Medical Research Institute | ||||
| Research Priority: Imaging, Biomarkers, & Molecular Pathology > Biomarkers & novel screening | ||||
| Award Type: STEP | ||||
| Dietary Fat, Fat Metabolizing Genes and Breast Cancer Risk | ||||
| University of Southern California | ||||
| Research Priority: Etiology > Hormones & nutrition | ||||
| Award Type: STEP | ||||
| Clinical Utility of Breast Cancer DNA Markers in Serum | ||||
| John Wayne Cancer Institute | ||||
| Research Priority: Imaging, Biomarkers, & Molecular Pathology > Biomarkers & novel screening | ||||
| Award Type: STEP | ||||
| PPARd Ligands for Inhibition of Breast Cancer Progression | ||||
| SRI International | ||||
| Research Priority: Innovative Treatments > New drug design | ||||
| Award Type: STEP | ||||
| In Vivo Effects of Chinese Herbal Extracts on Breast Cancer | ||||
| University of California, San Francisco | ||||
| Research Priority: Innovative Treatments > Hormone and chemotherapy targets | ||||
| Award Type: STEP | ||||
| Targeting the EphB4 Receptor to Inhibit Breast Tumor Growth | ||||
| The Burnham Institute for Medical Research | ||||
| Research Priority: Innovative Treatments > New drug design | ||||
| Award Type: STEP | ||||
| Herba Scutellaria Barbatae for Metastatic Breast Cancer | ||||
| University of California, San Francisco | ||||
| Research Priority: Innovative Treatments > Gene therapy & other treatments | ||||
| Award Type: STEP | ||||
| Novel Inhibitors of Rad51-DNA Repair in Breast Cancer | ||||
| Pangene Corporation | ||||
| Research Priority: Innovative Treatments > Immune therapy | ||||
| Award Type: STEP | ||||
Collaboration Awards: CRC (Community Research Collaboration) Pilot Awards Top
Topic-targeted Research Awards: RFA (Request for Applications) Top
| Migration and Breast Cancer Risk in Hispanics | ||||
| Cancer Prevention Institute of California | ||||
| Research Priority: Disparities > Disparities | ||||
| Award Type: RFA | ||||
| Pesticides and Breast Cancer in Hispanic Women | ||||
| Public Health Institute | ||||
| Research Priority: Disparities > Disparities | ||||
| Award Type: RFA | ||||
| HER-2/neu Gene Variations and Breast Cancer Risk | ||||
| University of Southern California | ||||
| Research Priority: Disparities > Disparities | ||||
| Award Type: RFA | ||||
| The Impact of Structure on Quality of Breast Cancer Care | ||||
| University of California, Los Angeles | ||||
| Research Priority: Health Policy & Health Services > Health Policy & Health Services | ||||
| Award Type: RFA | ||||
| Determinants of Breast Cancer Treatment in the Underserved | ||||
| University of California, Los Angeles | ||||
| Research Priority: Health Policy & Health Services > Health Policy & Health Services | ||||
| Award Type: RFA | ||||
| Geographic Variation in Breast Cancer Stage at Diagnosis | ||||
| University of California, Los Angeles | ||||
| Research Priority: Health Policy & Health Services > Health Policy & Health Services | ||||
| Award Type: RFA | ||||
| Genetic Aspects of Physiological Response During Lactation | ||||
| University of California, San Diego | ||||
| Research Priority: Biology of the Normal Breast > Breast function | ||||
| Award Type: RFA | ||||
| Role of IKKa in Mammary Gland Development | ||||
| University of California, San Diego | ||||
| Research Priority: Biology of the Normal Breast > Breast development | ||||
| Award Type: RFA | ||||
Career Development Awards: New Investigator Top
| Pathway-Specific Gene Expression in Breast Cancer Cells | ||||
| University of California, Davis | ||||
| Research Priority: Pathogenesis > Searching the unknown | ||||
| Award Type: New Investigator | ||||
| The Functions of BRCA2 in Repairing DNA Damage | ||||
| Lawrence Berkeley National Laboratory | ||||
| Research Priority: Pathogenesis > Mistakes on the master blueprint | ||||
| Award Type: New Investigator | ||||
| Enhanced HER-2 Directed Liposomal Therapeutics | ||||
| California Pacific Medical Center Research Institute | ||||
| Research Priority: Innovative Treatments > New drug design | ||||
| Award Type: New Investigator | ||||
| Patient-Individualized Chemotherapy in Breast Cancer | ||||
| University of California, Los Angeles | ||||
| Research Priority: Innovative Treatments > Hormone and chemotherapy targets | ||||
| Award Type: New Investigator | ||||
| Trypsin-like Proteases as Metastatic Agents in Breast Cancer | ||||
| University of California, Riverside | ||||
| Research Priority: Pathogenesis > Outbreak - how cancer spreads | ||||
| Award Type: New Investigator | ||||
| The PTEN/Akt Pathway in Ductal Carcinoma In Situ | ||||
| Cedars-Sinai Medical Center | ||||
| Research Priority: Pathogenesis > Unraveling the path to breast cancer | ||||
| Award Type: New Investigator | ||||
| Role of Chromatin Regulator in Breast Cell Growth | ||||
| University of California, Davis | ||||
| Research Priority: Biology of the Normal Breast > Breast function | ||||
| Award Type: New Investigator | ||||
| Tumor Suppression by Dystroglycan in Breast Epithelial Cells | ||||
| Lawrence Berkeley National Laboratory | ||||
| Research Priority: Pathogenesis > Unraveling the path to breast cancer | ||||
| Award Type: New Investigator | ||||
| Telomere Dynamics during Breast Development | ||||
| Lawrence Berkeley National Laboratory | ||||
| Research Priority: Biology of the Normal Breast > Breast aging | ||||
| Award Type: New Investigator | ||||
| Enhanced HER-2 Directed Liposomal Therapeutics | ||||
| Hermes Biosciences, Inc. | ||||
| Research Priority: Innovative Treatments > Immune therapy | ||||
| Award Type: New Investigator | ||||
